News | May 14, 2025
Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
The change of name has been carried on pursuant to the Scheme of Amalgamation
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Delivers robust earnings performance, successfully navigating a dynamic environment
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Subscribe To Our Newsletter & Stay Updated
